Johanna Falkenhorst

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Nilotinib revisited in GIST: Salvage use in patients with severe imatinib toxicity.

Nilotinib revisited in GIST: Salvage use in patients with severe imatinib toxicity.

Journal: The oncologist

Published: March 27, 2026

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Journal: JAMA oncology

Published: February 26, 2026

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Journal: Cancer research communications

Published: January 30, 2026

[68Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[18F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.

[68Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[18F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 14, 2025

Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).

Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 24, 2025

Correction: Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.

Correction: Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.

Journal: Journal of cancer research and clinical oncology

Published: January 11, 2025

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.

Journal: Journal of cancer research and clinical oncology

Published: August 09, 2024

Reply to Y. Xia et al.

Reply to Y. Xia et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 08, 2024

Prognostic factors in clear cell sarcoma: an analysis of soft tissue sarcoma in 43 cases.

Prognostic factors in clear cell sarcoma: an analysis of soft tissue sarcoma in 43 cases.

Journal: Journal of cancer research and clinical oncology

Published: June 12, 2024

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 26, 2024

Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.

Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 24, 2023

Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.

Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.

Journal: Cancers

Published: September 28, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026